Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.59 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.59 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.59 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.59 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.59 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.59 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.51 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.50 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12321327 | 0.91 | GRIN2D (0.53) | HRH3GRIN2DGRIN3BMAPTGRIN1 | |
| SCHEMBL82436 | 0.89 | GRIN2D (0.57) | HRH3GRIN2DGRIN3BMAPTGRIN1 | |
| SCHEMBL22137693 | 0.84 | LTA4H (0.63) | HRH3KCNA5PSMB1PSMB5PSMB2 | |
| SCHEMBL17198029 | 0.84 | LTA4H (0.59) | HRH3KCNA5DRD2LTA4H | |
| SCHEMBL25462936 | 0.83 | MAPT (0.64) | HRH3GRIN2DGRIN3BMAPTGRIN1 | |
| SCHEMBL15834053 | 0.82 | HRH3 (0.66) | HRH3PSMB1PSMB5PSMB2LTA4H | |
| SCHEMBL8337754 | 0.82 | HRH3 (0.70) | HRH3PSMB1PSMB5PSMB2ALDH1A1 | |
| SCHEMBL14054230 | 0.81 | KDM4E (0.63) | HRH3PSMB1PSMB5PSMB2DRD2 | |
| SCHEMBL17197050 | 0.81 | HRH3 (0.60) | HRH3GRIN2DGRIN3BMAPTGRIN1 | |
| SCHEMBL82435 | 0.80 | HRH3 (0.73) | HRH3PSMB1PSMB5PSMB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | HRH3 3986/4885GRIN2D 4507/4885GRIN3B 3837/4885 |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HRH3 3825/4885GRIN2D 3706/4885GRIN3B 3856/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HRH3 3902/4885GRIN2D 4620/4885GRIN3B 3547/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HRH3 1893/4885GRIN2D 4762/4885GRIN3B 4598/4885 |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HRH3 3825/4885GRIN2D 3706/4885GRIN3B 3856/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HRH3 3902/4885GRIN2D 4620/4885GRIN3B 3547/4885 |
| US-20150299134-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HRH3 3902/4885GRIN2D 4620/4885GRIN3B 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.